Tagged with IRA

pharma The country president for South Africa & Sub-Saharan Africa at AstraZeneca reveals why AstraZeneca sees Africa as the next frontier within the pharmaceutical industry, how their Research Trust looks to contribute to academic advancement on the continent, with a focus on non-communicable diseases, and how their Healthy Heart Africa program…

Hospira Carolina López-Torres joined Hospira Peru in 2011 following a dynamic career at Novartis. She discusses the early challenges she faced and the opportunities that the government’s hospital expansion plan has provided the market leader for pumps in Peru. What was the initial mission given to you when you first arrived?…

respiratory disease The country manager of an Italian pharmaceutical firm talks about the evolution of Algerian health needs and what her firm is doing to counter different forms of respiratory disease prevalent in the country. After eighteen years at Chiesi, what have been your main successes to date? On a personal note,…

R&D Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui Santos explains this process and how he plans to tackle the tough Portuguese marketplace.   Almirall has been in Portugal…

Generics Armando Esguerra, President of Chira Pharmaceuticals, Philippines, explains the concept of chirality, why it is relevant and extremely important in the pharmaceutical industry, and what have been the major challenges and successes of the company since its founding.    CHIRA Pharmaceuticals as a company was founded on the concept of…

Life Sciences The funding of Canada’s biotech industry has changed drastically in recent years. Peter Van Der Velden of Lumira Capital discusses those changes and how his venture capital business is adapting to this evolving environment. Lumira has been involved with numerous acquisitions over the years. Could you highlight a couple of…

Almirall Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well as the company’s choice to enter the Canadian market and what products they are introducing into it.   You started…

Array In 2010, you began your last interview with us by mentioning two things: that because of the nature of this affiliate’s portfolio—with only 35% of revenues generated by pharma at the time—Hospira’s strategy in Taiwan was a bit different than it was elsewhere in the world. You also said that…

Almirall Austria Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today? Nowadays Almirall Austria plays a significant role amongst the Almirall-affiliates. The Austrian subsidiary has been meeting and exceeding the expectations…

Savira pharmaceuticals You previously worked as CSO for onepharm; what was the motivation for creating Savira? OS: When I was working at onepharm, the organization was focused on anti-influenza and anti-inflammatory drug development. In late 2008, the enterprise management organization of the European Molecular Biology Laboratory (EMBL) was seeking for an industrial…

Hospira Hospira Mexico is not only the control centre for Central America and Caribbean operations, but it is the Latin American regional office. Why was such importance given to Mexico in this respect, and not for example, to Brazil? First of all, the Hospira model is a shared services model. It…

Hospira Taiwan What is exciting about the Taiwanese market for Hospira today? Hospira is a US-based company, which used to be part of Abbott Laboratories. A major part of the portfolio for the company is devices, which is mainly driven by its Medication Management Systems (MMS) portfolio. The rest of the company’s…